The Majority of Immunogenic Epitopes Generate CD4+ T Cells That Are Dependent on MHC Class II-Bound Peptide-Flanking Residues1
暂无分享,去创建一个
David L. Woodland | N. L. La Gruta | D. Woodland | D. Vignali | P. Adams | Kate M. Vignali | Paula Y. Arnold | Nicole L. La Gruta | Tim Miller | P. Scott Adams | Dario A. A. Vignali | P. Arnold | T. Miller | K. Vignali
[1] N. Pavletich,et al. Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.
[2] E. Unanue,et al. Identification of a major I-Ek-restricted determinant of hen egg lysozyme: limitations of lymph node proliferation studies in defining immunodominance and crypticity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Strominger,et al. Minute quantities of a single immunodominant foreign epitope are presented as large nested sets by major histocompatibility complex class II molecules , 1993, European journal of immunology.
[4] E. Unanue,et al. Mechanisms and consequences of peptide selection by the I‐Ak class II molecule , 1999, Immunological reviews.
[5] Partho Ghosh,et al. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3 , 1995, Nature.
[6] C Oseroff,et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones , 1994, The Journal of experimental medicine.
[7] D. Zaller,et al. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. , 1997, Immunity.
[8] Bernhard Hemmer,et al. Identification of High Potency Microbial and Self Ligands for a Human Autoreactive Class II–restricted T Cell Clone , 1997, The Journal of experimental medicine.
[9] D. Wiley,et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.
[10] R. Mariuzza,et al. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. , 2000, Journal of molecular biology.
[11] D. Wettstein,et al. pH dependence and exchange of high and low responder peptides binding to a class II MHC molecule. , 1992, The EMBO journal.
[12] J. Strominger,et al. NOD background genes influence T cell responses to GAD 65 in HLA-DQ8 transgenic mice. , 1999, Human immunology.
[13] A. Sette,et al. Analysis of lysozyme‐specific immune responses by synthetic peptides. I. Characterization of antibody and T cell‐mediated responses to the N‐terminal peptide of hen egg‐white lysozyme , 1986, European journal of immunology.
[14] J. Sidney,et al. Comparison of structural requirements for interaction of the same peptide with I-Ek and I-Ed molecules in the activation of MHC class II-restricted T cells. , 1991, Journal of immunology.
[15] R. Tisch,et al. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice , 1993, Nature.
[16] T. Leanderson,et al. Clonal Selection in B‐Cell Growth and Differentiation , 1987, Immunological reviews.
[17] L Gauthier,et al. Kinetics of T-cell Receptor Binding by Bivalent HLA-DR·Peptide Complexes That Activate Antigen-specific Human T-cells* , 2000, The Journal of Biological Chemistry.
[18] William S. Lane,et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.
[19] A Sette,et al. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.
[20] D. Wiley,et al. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. , 1998, Immunity.
[21] D. Vignali,et al. Immunoregulation of Th cells by naturally processed peptide antagonists. , 1999, Journal of immunology.
[22] H. Grey,et al. Structural requirements and biological significance of interactions between peptides and the major histocompatibility complex. , 1989, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[23] R. Tisch,et al. Determination of glutamic acid decarboxylase 65 peptides presented by the type I diabetes-associated HLA-DQ8 class II molecule identifies an immunogenic peptide motif. , 1999, Journal of immunology.
[24] P. A. Peterson,et al. Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues. , 1998, Immunity.
[25] E. Unanue,et al. Identification of two distinct properties of class II major histocompatibility complex-associated peptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Tobin,et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes , 1993, Nature.
[27] A Sette,et al. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. , 1992, Science.
[28] William Arbuthnot Sir Lane,et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.
[29] W. Taylor,et al. A sequence pattern common to T cell epitopes. , 1988, The EMBO journal.
[30] William Arbuthnot Sir Lane,et al. Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. , 1999, Journal of immunology.
[31] E. Sercarz,et al. Modulation of the immunogenicity of antigenic determinants by their flanking residues. , 1998, Immunology today.
[32] E. Unanue,et al. Specificity of the T cell receptor: two different determinants are generated by the same peptide and the I-Ak molecule. , 1985, Journal of immunology.
[33] Don C. Wiley,et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.
[34] W A Hendrickson,et al. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. , 1998, Immunity.
[35] D. Wiley,et al. Peptide binding to HLA‐DR1: a peptide with most residues substituted to alanine retains MHC binding. , 1990, The EMBO journal.
[36] E. Unanue,et al. Identification of the T-cell and Ia contact residues of a T-cell antigenic epitope , 1987, Nature.
[37] D. Fremont,et al. Structures of an MHC Class II Molecule with Covalently Bound Single Peptides , 1996, Science.
[38] A Sette,et al. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II. , 1998, Cellular immunology.
[39] J. Strominger,et al. Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor , 1994, The Journal of experimental medicine.
[40] A. Smolyar,et al. The crystal structure of a T cell receptor in complex with peptide and MHC class II. , 1999, Science.
[41] D. Vignali,et al. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. , 1997, Immunity.
[42] J. Strominger,et al. The two membrane proximal domains of CD4 interact with the T cell receptor , 1996, The Journal of experimental medicine.
[43] N. Shastri,et al. The Choice of T‐Cell Epitopes Utilized on a Protein Antigen Depends on Multiple Factors Distant from, as well as at the Determinant Site , 1987, Immunological Reviews.
[44] E. Unanue,et al. Analysis of the interaction of peptide hen egg white lysozyme (34-45) with the I-Ak molecule. , 1989, Journal of immunology.
[45] D. Wiley,et al. Structure of a covalently stabilized complex of a human αβ T‐cell receptor, influenza HA peptide and MHC class II molecule, HLA‐DR1 , 2000, The EMBO journal.
[46] A. Rudensky,et al. Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.
[47] E. Unanue,et al. Antigenic competition at the level of peptide-Ia binding. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[48] Maria V. Tejada-Simon,et al. Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.
[49] K. Garcia,et al. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. , 2000, Science.
[50] E. Unanue,et al. A negatively charged anchor residue promotes high affinity binding to the MHC class II molecule I-Ak. , 1996, Journal of immunology.
[51] A. Miller,et al. Dominance and crypticity of T cell antigenic determinants. , 1993, Annual review of immunology.
[52] E. Appella,et al. Mechanisms influencing the immunodominance of T cell determinants , 1988, The Journal of experimental medicine.
[53] Don C. Wiley,et al. Crystal Structure of HLA-DR2 (DRA*0101, DRB1*1501) Complexed with a Peptide from Human Myelin Basic Protein , 1998, The Journal of experimental medicine.
[54] A Sette,et al. The Interaction between Protein‐Derived Immunogenic Peptides and Ia , 1987, Immunological reviews.
[55] J. Rothbard. Major histocompatibility complex-peptide interactions. , 1989, Current opinion in immunology.
[56] H. Mcdevitt,et al. The role of MHC class II molecules in susceptibility to type I diabetes: identification of peptide epitopes and characterization of the T cell repertoire. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[57] E. Unanue,et al. Identification of the naturally processed form of hen egg white lysozyme bound to the murine major histocompatibility complex class II molecule I-Ak. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[58] Don C. Wiley,et al. Structure of a human insulin peptide–HLA-DQ8 complex and susceptibility to type 1 diabetes , 2001, Nature Immunology.
[59] E. Unanue,et al. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. , 2000, Immunity.